Skip to content
nuwiq-logo NUWIQ [Antihemophilic Factor (Recombinant)]
Main Menu
  • Intended for US Audiences Only
  • Go to Healthcare Professional Website »
  • Important Safety Information
  • Full Prescribing Information
  • Contact Us
  • Search Close
  • What is NUWIQ?
    • FVIII Treatment: Standard of Care
    • Learn about NUWIQ
    • Our Factor VIII Protein
  • Safety & Efficacy
    • Safety
    • Efficacy
  • Taking NUWIQ
    • Personalized Prophylaxis
    • Convenience/Flexible Dosing
    • Reconstitution Video
  • Patient Support
    • Factor My Way® Patient Support Program
    • Free Trial Program
    • Co-Pay & Reimbursement Assistance
    • Patient Testimonials
  • Connect
    • Patient Experience Manager
    • Find Your HTC
  • Intended for US Audiences Only
  • Go to Healthcare Professional Website »

NUWIQ® Patient Site Map

Home Site Map

Pages

  • Home
  • Patents
  • What is NUWIQ?
    • FVIII Treatment: Standard of Care
    • Learn About NUWIQ
    • Our Factor VIII Protein
  • Safety
    • Efficacy
  • Taking NUWIQ
    • Personalized Prophylaxis
    • Convenience/Flexible Dosing
    • Reconstitution Video
  • Patient Support
    • Factor My Way® Patient Support Program
    • Free Trial Program
    • NUWIQ® Co-Pay & Reimbursement Assistance
    • Patient Testimonials
  • Connect
    • Patient Experience Manager
    • Find a Treatment Center
  • Important Safety Information
  • Contact Us
  • Site Map
Indications and Important Safety Information for NUWIQ® [Antihemophilic Factor (Recombinant)]

Please see NUWIQ full Prescribing Information. Instructions For Use

Indications and Important Safety Information for NUWIQ® [Antihemophilic Factor (Recombinant)]

Please see NUWIQ full Prescribing Information. Instructions For Use

Indications and Use

NUWIQ® is a recombinant antihemophilic factor [coagulation factor VIII (Factor VIII)] indicated in pediatric and adult patients with Hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes. NUWIQ® is not indicated for the treatment of von Willebrand Disease.

Contraindications

NUWIQ is contraindicated in patients who have manifested life-threatening hypersensitivity reactions, including anaphylaxis, to the product or its components.

Warnings and Precautions

Hypersensitivity reactions, including anaphylaxis, are possible with NUWIQ. Early signs of hypersensitivity reactions that can progress to anaphylaxis may include angioedema, chest tightness, dyspnea, wheezing, urticaria, or pruritus. Immediately discontinue administration and initiate appropriate treatment if hypersensitivity reactions occur.

The formation of neutralizing antibodies (inhibitors) to Factor VIII can occur following the administration of NUWIQ. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests. If the plasma Factor VIII level fails to increase as expected, or if bleeding is not controlled after NUWIQ administration, suspect the presence of an inhibitor (neutralizing antibody).

Adverse Reactions

The most frequently occurring adverse reactions (>5%) in clinical trials were upper respiratory tract infection, headache, fever, cough, lower respiratory tract infection, rhinitis, chills, abdominal pain, arthralgia, anemia, and pharyngitis.

Please See NUWIQ full Prescribing Information.  Instructions For Use

Scroll Back to Top
Octapharma logo
  • Facebook
  • Home
  • Site Map
  • Terms of Use
  • Privacy Policy
  • California Required Statements
  • Contact Us
© 2025 Octapharma USA Inc. All Rights Reserved
  • About Octapharma
  • NUW-0606

This website uses cookies and stores information on your computer. Some of them are essential to improve our website and your user experience. By using this website, you agree to the use of these cookies. Please check our privacy policy for more details.